IntraPace
Founded Year
2001Stage
Debt - II | DeadTotal Raised
$69.07MLast Raised
$620KAbout IntraPace
IntraPace has developed an implantable system to treat obesity. The abiliti system is designed to be implanted via standard laparoscopic instruments without making any changes to the anatomy of the digestive system or placing any limitations on what a person can eat or drink. IntraPace's abiliti system is designed to be an intelligent obesity intervention. Once implanted and activated, the abiliti system is designed to detect when a person consumes food or drink. When food or drink is detected, the system delivers a series of low-energy electrical impulses to the stomach intended to create a feeling of fullness. These electrical impulses are customized to the needs of each individual patient. The system also tracks patient activity levels, providing a comprehensive view of food consumption and exercise trends. This information may be used by patients and their healthcare providers to reinforce healthy behaviors and activities that lead to weight loss. The abiliti system is intended to enable patients to achieve and sustain significant weight loss without the complications, lifestyle restrictions, and substantial anatomical changes associated with the current bariatric surgeries.
Missing: IntraPace's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: IntraPace's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
IntraPace Patents
IntraPace has filed 28 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/26/2002 | 6/6/2017 | Digestive system, Gastrointestinal tract disorders, Transcription factors, Ion channels, Stomach | Grant |
Application Date | 3/26/2002 |
|---|---|
Grant Date | 6/6/2017 |
Title | |
Related Topics | Digestive system, Gastrointestinal tract disorders, Transcription factors, Ion channels, Stomach |
Status | Grant |
Latest IntraPace News
May 6, 2021
| ReShape Lifesciences, Inc., IntraPace Inc., Changzhou Ruishen Medical Equipment Co., Ltd & so on… The worldwide uptake of gastric electric stimulators is anticipated to witness hefty demand in 2019, representing a rigorous 6.6% y-o-y growth, while reaching a valuation of approx. US$ 188.4 Mn in 2026. As per Future Market Insights (FMI) report on gastric electric stimulators market for the forecast period 2018–2026, gastric electric stimulators’ demand is anticipated to be accelerated by a host of pacesetters. The FMI report on gastric electric stimulators market opines that sales of gastric electric stimulators are likely to witness sheer proliferation in coming time, on the back of burgeoning minimally invasive procedures, surging reported cases of gastroparesis, and encouraging reimbursement schemes. Growing pervasiveness of gastroparesis has been identified as the primary demand generating factor making gastric electric stimulators highly preferred treatment substitute for such arduous diseases. Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-8992 “Enterra system, a critical medical device which is highly used to treat Gastroparesis has received FDA approval as a humanitarian use device, on the back of its potential to treat or diagnose a disease or condition affecting approx. 4000 individuals annually in the United States. Though conditionally, the American College of Gastroenterology (ACG) also recommends adoption of gastric electric stimulators for individuals with chronic, stubborn nausea and vomiting caused by Gastroparesis. The gastric electric stimulators, like Enterra, is a battery-based gastric neurostimulator, which is usually rooted under the skin in lower abdomen part of the body”, Senior Analyst, FMI. As per the FMI report on gastric electric stimulators market, considering the rareness of Gastroparesis in tandem with the widespread occurrence of gastric-related issues, investments in R&D and clinical studies have considerably increased in the recent past. Moreover, the growing adoption of gastric electric stimulators as an effective substitute to gastrectomy in patients with end-stage gastric dysfunction, is projected to accelerate the demand for gastric electric stimulators considerably by the end of 2026. High-Frequency Product Type Gaining Colossal Traction According to the FMI report, high-frequency variant of gastric electric stimulators are witnessing mammoth traction as being one of the most compelling product type, in comparison to the low-frequency variant of gastric electric stimulators. The FMI gastric electric stimulators market report opines that high-frequency variant of gastric electric stimulators aren’t just minimally invasive and extremely patient-friendly in terms of insertion, but also encompass comparatively longer battery life than the low-frequency variant of gastric electric stimulators. Additionally, as per FMI analysis, with over 75% gastric stimulators market share, high-frequency variant of gastric electric stimulators is likely to ameliorate the Gastroparetic treatment landscape. Preview Analysis Global Gastric Electric Stimulators Market Segmentation By Product Type (High Frequency GES Devices, Low Frequency GES Devices); By Indication (Gastroparesis, Obesity, Refractory Nausea, Others); By End User (Hospitals, Outpatients Centers): https://www.futuremarketinsights.com/reports/gastric-electric-stimulators-market Though, gastric electrical stimulation makes the most viable treatment option for chronic drug-refractory nausea and vomiting peripheral to Gastroparesis of idiopathic or diabetic etiology, Enterra Therapy associated risks remain exceptionally high, thereby hampering the adoption of gastric electric stimulators. North America Gastric Electric Stimulators Market Remains Lucrative FMI gastric electric stimulators report opines that North America is likely to retain its dominance in the gastric electric stimulators market between 2018 and 2026. According to the FMI report on gastric electric stimulators market, growing investments in medical studies and R&D activities, continuing technical advancements and innovations, coupled with the presence of several leading market players, are other key factors paving way for lucrative opportunities in across North America gastric electric stimulators market. According to gastric electric stimulators market report, the worldwide gastric electric stimulators market will continue to remain highly consolidated with market Mughals contributing approx. 5o% revenue share to global gastric electric stimulators market, owing to their superior product offering and extensive demographic presence. Further, to capitalize on the growing demand for gastric electric stimulators, leading market players are poised to indulge into collaborations and acquisitions of local players, to reinforce their market presence. Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-8992 More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence: Cranial Stabilisation Devices Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 to 2027 Patient-Controlled Analgesia Pumps Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 to 2026 Orthobiologics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2027 About us Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact us
IntraPace Frequently Asked Questions (FAQ)
When was IntraPace founded?
IntraPace was founded in 2001.
Where is IntraPace's headquarters?
IntraPace's headquarters is located at 2051 Ringwood Ave, San Jose.
What is IntraPace's latest funding round?
IntraPace's latest funding round is Debt - II.
How much did IntraPace raise?
IntraPace raised a total of $69.07M.
Who are the investors of IntraPace?
Investors of IntraPace include Threshold Ventures, Halo Funds, InCube Ventures, ePlanet Capital, Intellectual Ventures and 10 more.
Who are IntraPace's competitors?
Competitors of IntraPace include EndoGastric Solutions, Endologix, ValenTx, Entellus Medical, ReShape Medical and 11 more.
Compare IntraPace to Competitors
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
ValenTx is developing a new therapy to treat patients with obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. The company's technology mimics the therapeutic mechanisms of a Roux-en-Y gastric bypass, and does this with a non-surgical, endoluminal bypass device.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
EndoVx is developing a medical device system for non-invasively treating obesity. The procedure is quick and done on an out-patient basis.
EndoMetabolic Solutions is developing a medical device for the surgical treatment of obesity.
Abla-Tx Inc is a private company founded in 2005 to develop a software based algorithm to monitor thermal ablation of tumors. Abla-Tx has been formed to help guide minimally invasive methods for the treatment of all malignant and benign solid tumors. A patented method of monitoring temperature during thermal ablation in conjunction with CT and digital x-ray imaging will be developed and commercialized. Regulatory approval will be sought to allow the sale of a software based thermal mapping system that will be used in conjunction with CT and planar x-ray imaging systems.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.